Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

High-dose melphalan 140 mg/m(2) is the standard of care for patients with multiple myeloma (MM) with renal insufficiency (RI). Palifermin as a cytoprotective agent has demonstrated efficacy in reducing the intensity and duration of oral mucositis (OM) in patients who receive intensive chemotherapy/r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Abidi, Muneer H., Agarwal, Rishi, Ayash, Lois, Deol, Abhinav, Al-Kadhimi, Zaid, Abrams, Judith, Cronin, Simon, Ventimiglia, Marie, Lum, Lawrence, Zonder, Jeffrey, Ratanatharathorn, Voravit, Uberti, Joseph
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782285/
https://ncbi.nlm.nih.gov/pubmed/22453252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2012.03.010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares